{"id":"bcg","rwe":[],"_fda":{"id":"223f2b2b-87d0-4beb-b00a-16a2b041a5bc","set_id":"c9b74876-e665-442b-87ad-b7333bc9a67a","openfda":{"nui":["N0000183904","N0000183364","M0022454","M0002239","N0000183906","N0000183884","N0000009357"],"upc":["0300520602020"],"unii":["2XQ558L16Z"],"route":["INTRAVESICAL"],"rxcui":["213744","1653484"],"spl_id":["223f2b2b-87d0-4beb-b00a-16a2b041a5bc"],"brand_name":["TICE BCG"],"spl_set_id":["c9b74876-e665-442b-87ad-b7333bc9a67a"],"package_ndc":["0052-0602-01","0052-0602-02"],"product_ndc":["0052-0602"],"generic_name":["BACILLUS CALMETTE-GUERIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Vaccines, Attenuated [CS]","BCG Vaccine [CS]"],"pharm_class_pe":["Actively Acquired Immunity [PE]","Increased Macrophage Proliferation [PE]","Increased Immunologically Active Molecule Activity [PE]"],"substance_name":["BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN"],"pharm_class_epc":["Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","Live Attenuated Bacillus Calmette-Guerin Immunotherapy [EPC]"],"manufacturer_name":["Merck Sharp & Dohme LLC"],"application_number":["BLA102821"],"is_original_packager":[true]},"version":"22","warnings":["WARNINGS BCG LIVE (TICE ® BCG) is not a vaccine for the prevention of cancer. BCG Vaccine, not BCG LIVE (TICE BCG), should be used for the prevention of tuberculosis. For vaccination use, refer to BCG Vaccine prescribing information. Handling Precautions TICE BCG is an infectious agent. Physicians using this product should be familiar with the literature on the prevention and treatment of BCG-related complications, and should be prepared in such emergencies to contact an infectious disease specialist with experience in treating the infectious complications of intravesical BCG. The treatment of the infectious complications of BCG requires long-term, multiple-drug antibiotic therapy. Special culture media are required for mycobacteria, and physicians administering intravesical BCG or those caring for these patients should have these media readily available. BCG Infection Instillation of TICE BCG with an actively bleeding mucosa may promote systemic BCG infection. Treatment should be postponed for at least 1 week following transurethral resection, biopsy, traumatic catheterization, or gross hematuria. Systemic BCG Reaction Deaths have been reported as a result of systemic BCG infection and sepsis. 2,3 Patients should be monitored for the presence of symptoms and signs of toxicity after each intravesical treatment. Febrile episodes with flu-like symptoms lasting more than 72 hours, fever ≥103°F, systemic manifestations increasing in intensity with repeated instillations, or persistent abnormalities of liver function tests suggest systemic BCG infection and may require antituberculous therapy. Local symptoms (prostatitis, epididymitis, orchitis) lasting more than 2 to 3 days may also suggest active infection (see WARNINGS, Management of Serious BCG Complications section). Laboratory Tests The use of TICE BCG may cause tuberculin sensitivity. Since this is a valuable aid in the diagnosis of tuberculosis, it is advisable to determine the tuberculin reactivity by PPD skin testing before treatment. Antimicrobial Therapy Intravesical instillations of BCG should be postponed during treatment with antibiotics, since antimicrobial therapy may interfere with the effectiveness of TICE BCG (see PRECAUTIONS ). TICE BCG should not be used in individuals with concurrent infections. Bladder Capacity Small bladder capacity has been associated with increased risk of severe local reactions and should be considered in deciding to use TICE BCG therapy. Management of Serious BCG Complications. Acute, localized irritative toxicities of TICE BCG may be accompanied by systemic manifestations, consistent with a \"flu-like\" syndrome. Systemic adverse effects of 1 to 2 days' duration such as malaise, fever, and chills often reflect hypersensitivity reactions. However, symptoms such as fever of ≥ 38.5°C (101.3°F), or acute localized inflammation such as epididymitis, prostatitis, or orchitis persisting longer than 2 to 3 days suggest active infection, and evaluation for serious infectious complication should be considered. In patients who develop persistent fever or experience an acute febrile illness consistent with BCG infection, 2 or more antimycobacterial agents should be administered while diagnostic evaluation, including cultures, is conducted. BCG treatment should be discontinued. Negative cultures do not necessarily rule out infection. Physicians using this product should be familiar with the literature on prevention, diagnosis, and treatment of BCG-related complications and, when appropriate, should consult an infectious disease specialist or other physician with experience in the diagnosis and treatment of mycobacterial infections. TICE BCG is sensitive to the most commonly used antituberculous agents (isoniazid, rifampin, and ethambutol). TICE BCG is not sensitive to pyrazinamide."],"pregnancy":["Pregnancy Animal reproduction studies have not been conducted with TICE BCG. It is also not known whether TICE BCG can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. TICE BCG should not be given to a pregnant woman except when clearly needed. Women should be advised not to become pregnant while on therapy."],"overdosage":["OVERDOSAGE Overdosage occurs if more than 1 vial of TICE ® BCG is administered per instillation. If overdosage occurs, the patient should be closely monitored for signs of active local or systemic BCG infection. For acute local or systemic reactions suggesting active infection, an infectious disease specialist experienced in BCG complications should be consulted."],"references":["REFERENCES DeJager R, Guinan P, Lamm D, Khanna O, Brosman S, DeKernion J, et al. Long-Term Complete Remission in Bladder Carcinoma in Situ with Intravesical TICE Bacillus Calmette Guerin. Urology 1991;38:507–513. Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, Grossman HB, Scardino PT. Fatal Sepsis Following Intravesical Bacillus Calmette-Guerin Administration For Bladder Cancer. J Urol 1990;144:1328–1330. Lamm DL, van der Meijden APM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and Treatment of Complications of Bacillus Calmette-Guerin Intravesical Therapy in Superficial Bladder Cancer. J. Urol 1992;147:596–600. Stone MM, Vannier AM, Storch SK, Nitta AT, Zhang Y. Brief Report: Meningitis Due to Iatrogenic BCG Infection in Two Immunocompromised Children. NEJM 1995:333:561–563. Steg A, Leleu C, Debre B, Gibod-Boccon L, Sicard D. Systemic Bacillus Calmette-Guerin Infection in Patients Treated by Intravesical BCG Therapy for Superficial Bladder Cancer. EORTC Genitourinary Group Monograph 6: BCG in Superficial Bladder Cancer . Edited by F.M. J. Debruyne, L. Denis and A.P.M. van der Meijden. New York: Alan R. Liss Inc., pp. 325–334. van der Meijden, APM. Practical Approaches to the Prevention and Treatment of Adverse Reactions to BCG. Eur Urol 1995;27(suppl 1):23–28. Lamm DL, Blumenstein BA, Crawford ED, Crissman JD, Lowe BA, Smith JA, Sarosdy MF, Schellhammer PF, Sagalowsky AI, Messing EM, et al. Randomized Intergroup Comparison of Bacillus Calmette-Guerin Immunotherapy and Mitomycin C Chemotherapy Prophylaxis in Superficial Transitional Cell Carcinoma of the Bladder. Urol Oncol 1995;1:119–126. Witjes JA, van der Meijden APM, Witjes WPJ, et al. A Randomized Prospective Study Comparing Intravesical Instillations of Mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 Tumours and Primary Carcinoma In Situ of the Urinary Bladder. Eur J Cancer 1993;29A(12):1672–1676."],"description":["DESCRIPTION TICE ® BCG (BCG LIVE) for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. 1 The TICE ® seed lot used in this TICE ® BCG preparation was developed at the University of Illinois from two BCG strains originated at the Pasteur Institute. The medium in which the BCG organism is grown for preparation of the freeze-dried cake is composed of the following ingredients: glycerin, asparagine, citric acid, potassium phosphate, magnesium sulfate, and iron ammonium citrate. The final preparation prior to freeze drying also contains lactose. The freeze-dried BCG preparation is delivered in glass vials, each containing 1 to 8 × 10 8 colony forming units (CFU) of TICE BCG which is equivalent to approximately 50 mg wet weight. Determination of in vitro potency is achieved through colony counts derived from a serial dilution assay. A single dose consists of 1 reconstituted vial (see DOSAGE AND ADMINISTRATION ). For intravesical use the entire vial is reconstituted with sterile saline. TICE BCG is viable upon reconstitution. No preservatives have been added."],"precautions":["PRECAUTIONS General TICE ® BCG contains live mycobacteria and should be prepared and handled using aseptic technique (see DOSAGE AND ADMINISTRATION, Preparation of Agent section). BCG infections have been reported in health care workers preparing BCG for administration. Needle stick injuries should be avoided during the handling and mixing of TICE BCG. Nosocomial infections have been reported in patients receiving parenteral drugs which were prepared in areas in which BCG was prepared. 4 BCG is capable of dissemination when administered by intravesical route, and serious reactions, including fatal infections, have been reported in patients receiving intravesical BCG. 3 Care should be taken not to traumatize the urinary tract or to introduce contaminants into the urinary system. Seven to 14 days should elapse before TICE BCG is administered following TUR, biopsy, or traumatic catheterization. TICE BCG should be administered with caution to persons in groups at high risk for HIV infection. Laboratory Tests The use of TICE BCG may cause tuberculin sensitivity. It is advisable to determine the tuberculin reactivity of patients receiving TICE BCG by PPD skin testing before treatment is initiated. Information for Patients TICE BCG is retained in the bladder for 2 hours and then voided. Patients should void while seated in order to avoid splashing of urine. For the 6 hours after treatment, urine voided should be disinfected for 15 minutes with an equal volume of household bleach before flushing. Patients should be instructed to increase fluid intake in order to \"flush\" the bladder in the hours following BCG treatment. Patients may experience burning with the first void after treatment. Patients should be attentive to side effects, such as fever, chills, malaise, flu-like symptoms, or increased fatigue. If the patient experiences severe urinary side effects, such as burning or pain on urination, urgency, frequency of urination, blood in urine, or other symptoms such as joint pain, cough, or skin rash, the physician should be notified. Drug Interaction Drug combinations containing immunosuppressants and/or bone marrow depressants and/or radiation interfere with the development of the immune response and should not be used in combination with TICE BCG. Antimicrobial therapy for other infections may interfere with the effectiveness of TICE BCG. There are no data to suggest that the acute, local urinary tract toxicity common with BCG is due to mycobacterial infection, and antituberculosis drugs (e.g., isoniazid) should not be used to prevent or treat the local, irritative toxicities of TICE BCG. Carcinogenesis, Mutagenesis, Impairment of Fertility TICE BCG has not been evaluated for its carcinogenic, mutagenic potentials, or impairment of fertility. Pregnancy Animal reproduction studies have not been conducted with TICE BCG. It is also not known whether TICE BCG can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. TICE BCG should not be given to a pregnant woman except when clearly needed. Women should be advised not to become pregnant while on therapy. Nursing Mothers It is not known whether TICE BCG is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from TICE BCG in nursing infants, it is advisable to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness of TICE BCG for the treatment of superficial bladder cancer in pediatric patients have not been established. Geriatric Use Of the total number of subjects in clinical studies of TICE BCG, the average age was 66 years old. No overall difference in safety or effectiveness was observed between older and younger subjects. Other reported clinical experience has not identified differences in response between elderly and younger patients, but greater sensitivity of some older individuals to BCG cannot be ruled out."],"how_supplied":["HOW SUPPLIED TICE ® BCG is supplied in a box of 1 single-dose vial of TICE BCG. Each vial contains 1 to 8 × 10 8 CFU, which is equivalent to approximately 50 mg (wet weight), as lyophilized (freeze-dried) powder, NDC 0052-0602-02. STORAGE The intact vials of TICE ® BCG should be stored refrigerated, at 2–8°C (36–46°F). This agent contains live bacteria and should be protected from direct sunlight. The product should not be used after the expiration date printed on the label."],"boxed_warning":["WARNING TICE ® BCG contains live, attenuated mycobacteria. Because of the potential risk for transmission, prepare, handle, and dispose of TICE ® BCG as a biohazard material (see PRECAUTIONS and DOSAGE AND ADMINISTRATION sections). BCG infections have been reported in health care workers, primarily from exposures resulting from accidental needle sticks or skin lacerations during the preparation of BCG for administration. Nosocomial infections have been reported in patients receiving parenteral drugs that were prepared in areas in which BCG was reconstituted. BCG is capable of dissemination when administered by the intravesical route, and serious infections, including fatal infections, have been reported in patients receiving intravesical BCG (see WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS sections)."],"geriatric_use":["Geriatric Use Of the total number of subjects in clinical studies of TICE BCG, the average age was 66 years old. No overall difference in safety or effectiveness was observed between older and younger subjects. Other reported clinical experience has not identified differences in response between elderly and younger patients, but greater sensitivity of some older individuals to BCG cannot be ruled out."],"pediatric_use":["Pediatric Use Safety and effectiveness of TICE BCG for the treatment of superficial bladder cancer in pediatric patients have not been established."],"effective_time":"20260220","nursing_mothers":["Nursing Mothers It is not known whether TICE BCG is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from TICE BCG in nursing infants, it is advisable to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"clinical_studies":["CLINICAL STUDIES Carcinoma in situ (Bladder Cancer) To evaluate the efficacy of intravesical administration of TICE ® BCG in the treatment of carcinoma in situ , patients were identified who had been treated with TICE BCG under 6 different Investigational New Drug (IND) applications in which the most important shared aspect was the use of an induction plus maintenance schedule. Patients received TICE BCG (50 mg; 1 to 8 x 10 8 CFU) intravesically, once weekly for at least 6 weeks and once monthly thereafter for up to 12 months. A longer maintenance was given in some cases. The study population consisted of 153 patients, 132 males, 19 females, and 2 unidentified as to gender. Thirty patients lacking baseline documentation of CIS and 4 patients lost to follow-up were not evaluable for treatment response. Therefore, 119 patients were available for efficacy evaluation. The mean age was 69 years (range: 38–97 years). There were 2 categories of clinical response: (1) Complete Histological Response (CR), defined as complete resolution of carcinoma in situ documented by cystoscopy and cytology, with or without biopsy; and (2) Complete Clinical Response Without Cytology (CRNC), defined as an apparent complete disappearance of tumor upon cystoscopy. The results of a 1987 analysis of the evaluable patients are shown in Table 1 . Table 1: The Response of Patients With CIS Bladder Cancer in 6 IND Studies Entered Evaluable CR CRNC Overall response No. (%) of patients 153 119 (78%) 54 (46%) 36 (30%) 90 (76%) A 1989 update of these data is presented in Table 2 . The median duration of follow-up was 47 months. Table 2: Follow-up Response of Patients With CIS Bladder Cancer in 6 IND Studies 1989 Status of 90 Responders (CR or CRNC) Response 1987/CR n=54 1987/CRNC n=36 1987 Response n=90 Percent CR 30 15 45 50 CRNC 0 0 0 0 Unrelated deaths 6 6 12 13 Failure 18 15 33 37 There was no significant difference in response rates between patients with or without prior intravesical chemotherapy. The median duration of response, calculated from the Kaplan-Meier curve as median time to recurrence, is estimated at 4 years or greater. The incidence of cystectomy for 90 patients who achieved a complete response (CR or CRNC) was 11%. The median time to cystectomy in patients who achieved a complete response (CR or CRNC) exceeded 74 months. TaT1 Bladder Cancer The efficacy of intravesical TICE BCG in preventing the recurrence of a TaT1 bladder cancer after complete transurethral resection of all papillary tumors was evaluated in 2 open-label, randomized phase III clinical trials. Initial diagnosis of patients included in the studies was determined by cystoscopic biopsies. One was conducted by the Southwestern Oncology Group (SWOG) in patients at high risk of recurrence. High risk was defined as 2 occurrences of tumor within 56 weeks, any stage T1 tumor, or 3 or more tumors presenting simultaneously. The second study was conducted at the Nijmegen University Hospital; Nijmegen, The Netherlands. In this study patients were not selected for high risk of recurrence. In both studies treatment was initiated between 1 and 2 weeks after transurethral resection (TUR). SWOG Trial (study 8795) In the SWOG trial (study 8795) patients were randomized to TICE BCG or mitomycin C (MMC). Both drugs were given intravesically weekly for 6 weeks, at 8 and 12 weeks, and then monthly for a total treatment duration of 1 year. Cystoscopy and urinary cytology were performed every 3 months for 2 years. Patients with progressive disease or residual or recurrent disease at or after the 6 month follow-up were removed from the study and were classified as treatment failures. A total of 469 patients was entered into the study: 237 to the TICE BCG arm and 232 to the MMC arm. Twenty-two patients were subsequently found to be ineligible, and 66 patients had concurrent CIS, and were analyzed separately. Four patients were lost to follow-up, leaving 191 evaluable patients in the TICE BCG arm and 186 in the MMC arm. Of the patients, 84% were male and 16% were female. The average age of these patients was 65 years old. The Kaplan-Meier estimates of 2-year disease-free survival are shown in Table 3 . The difference in disease-free survival time between the 2 groups was statistically significant by the log rank test ( P =0.03). The 95% confidence interval of the difference in 2-year disease-free survival was 12% ± 10%. No statistically significant differences between the groups were noted in time to tumor progression, tumor invasion, or overall survival. Table 3: Results of SWOG Study 8795 TICE BCG Arm N=191 MMC Arm N=186 Estimated disease-free survival at 2 years 57% 45% 95% Confidence Interval (CI) (50%, 65%) (38%, 53%) Nijmegen Study In the Nijmegen study, the efficacy of 3 treatments was compared: TICE substrain BCG, Rijksinstituut voor Volksgezondheid en Milieuhygiene substrain BCG (BCG-RIVM), and MMC. TICE BCG and BCG-RIVM were given intravesically weekly for 6 weeks. In contrast to the SWOG study, maintenance BCG was not given. Mitomycin C was given intravesically weekly for 4 weeks and then monthly for a total duration of treatment of 6 months. Cystoscopy and urinary cytology were performed every 3 months until recurrence. A total of 469 patients was enrolled and randomized. Thirty-two patients were not evaluable, 17 were ineligible, 15 were withdrawn before treatment, and 50 had concurrent CIS and were analyzed separately, leaving 387 evaluable patients: 117 in the TICE BCG arm, 134 in the BCG-RIVM arm, and 136 in the MMC arm. Twenty-eight patients (24%) in the TICE BCG arm, 32 patients (24%) in the BCG-RIVM arm, and 24 patients (18%) in the MMC arm had TaG1 tumors. The median duration of follow-up was 22 months (range: 3–54 months). The Kaplan-Meier estimates of 2-year disease-free survival are shown in Table 4 . The differences in disease-free survival among the 3 arms were not statistically significant by the log-rank test ( P =0.08). Table 4: Results of Nijmegen Study TICE BCG Arm N=117 BCG-RIVM Arm N=134 MMC Arm N=136 Estimated disease-free survival at 2 years 53% 62% 64% 95% Confidence Interval (CI) (44%, 64%) (53%, 72%) (55%, 74%) In both the SWOG 8795 study and the Nijmegen study, acute toxicity was more common, and usually more severe, with TICE BCG than with MMC (see ADVERSE REACTIONS )."],"laboratory_tests":["Laboratory Tests The use of TICE BCG may cause tuberculin sensitivity. It is advisable to determine the tuberculin reactivity of patients receiving TICE BCG by PPD skin testing before treatment is initiated."],"adverse_reactions":["ADVERSE REACTIONS Symptoms of bladder irritability, related to the inflammatory response induced, are reported in approximately 60% of patients receiving TICE ® BCG. The symptoms typically begin 4 to 6 hours after instillation and last 24 to 72 hours. The irritative side effects are usually seen following the third instillation, and tend to increase in severity after each administration. The irritative bladder adverse effects can usually be managed symptomatically with products such as pyridium, propantheline bromide, oxybutynin chloride, and acetaminophen. The mechanism of action of the irritative side effects has not been firmly established, but is most consistent with an immunological mechanism. 3 There is no evidence that dose reduction or antituberculous drug therapy can prevent or lessen the irritative toxicity of TICE BCG. \"Flu-like\" symptoms (malaise, fever, and chills) which may accompany the localized, irritative toxicities often reflect hypersensitivity reactions which can be treated symptomatically. Antihistamines have also been used. 5 Adverse reactions to TICE BCG tend to be progressive in frequency and severity with subsequent instillation. Delay or postponement of subsequent treatment may or may not reduce the severity of a reaction during subsequent instillation. Although uncommon, serious infectious complications of intravesical BCG have been reported. 2,3,6 The most serious infectious complication of BCG is disseminated sepsis with associated mortality. In addition, M. bovis infections have been reported in lung, liver, bone, bone marrow, kidney, regional lymph nodes, and prostate in patients who have received intravesical BCG. Systemic infections may be manifested by pneumonitis, hepatitis, cytopenia, vasculitis, infective aneurysm and/or sepsis after a period of fever and malaise during which symptoms progressively increase. Some male genitourinary tract infections (orchitis/epididymitis) have been resistant to multiple-drug antituberculous therapy and required orchiectomy. If a patient develops persistent fever or experiences an acute febrile illness consistent with BCG infection, BCG treatment should be discontinued and the patient immediately evaluated and treated for systemic infection (see WARNINGS ). The local and systemic adverse reactions reported in a review of 674 patients with superficial bladder cancer, including 153 patients with carcinoma in situ , are summarized in Table 5 . Table 5: Summary of Adverse Effects Seen in 674 Patients With Superficial Bladder Cancer, Including 153 With Carcinoma in Situ Percent of patients Percent of patients Adverse event N Overall (Grade ≥3) Adverse event N Overall (Grade ≥3) Dysuria 401 60% (11%) Arthritis/myalgia 18 3% (<1%) Urinary frequency 272 40% (7%) Headache/dizziness 16 2%(0) Flu-like syndrome 224 33% (9%) Urinary incontinence 16 2% (0) Hematuria 175 26% (7%) Anorexia/weight loss 15 2% (<1%) Fever 134 20% (8%) Urinary debris 15 2% (<1%) Malaise/fatigue 50 7% (0) Allergy 14 2% (<1%) Cystitis 40 6% (2%) Cardiac (unclassified) 13 2% (1%) Urgency 39 6% (1%) Genital inflammation/ Nocturia 30 5% (1%) abscess 12 2% (<1%) Cramps/pain 27 4% (1%) Respiratory (unclassified) 11 2% (<1%) Rigors 22 3% (1%) Urinary tract infection 10 2% (1%) Nausea/vomiting 20 3% (<1%) Abdominal pain 10 2% (1%) The following adverse events were reported in ≤1% of patients: anemia, BCG sepsis, coagulopathy, contracted bladder, diarrhea, epididymitis/prostatitis, hepatic granuloma, hepatitis, leukopenia, neurologic (unclassified), orchitis, pneumonitis, pyuria, rash, thrombocytopenia, urethritis, and urinary obstruction. In SWOG study 8795, toxicity evaluations were available on a total of 222 TICE BCG-treated patients and 220 MMC-treated patients. Direct bladder toxicity (cramps, dysuria, frequency, urgency, hematuria, hemorrhagic cystitis, or incontinence) was seen more often with TICE BCG with 356 events, compared to 234 events for MMC. Grade ≤2 toxicity was seen significantly more frequently following TICE BCG treatment ( P =0.003). No life-threatening toxicity was seen in either arm. Systemic toxicity with TICE BCG was markedly increased compared to that of MMC, with 181 events for TICE BCG compared to 80 for MMC. The frequency of toxicity was increased in all grades, particularly for grades 2 and 3. The most common complaints were malaise, fatigue and lethargy, fever, and abdominal pain. Thirty-two TICE BCG patients were reported to have been treated with isoniazid. Five TICE BCG patients had liver enzyme elevation, including 2 with grade 3 elevations. Eighteen of the 222 (8.1%) TICE BCG patients failed to complete the prescribed protocol compared to 6.2% in the MMC group. Table 6 summarizes the most common adverse reactions reported in this trial. 7 Table 6: Most Common Adverse Reactions in SWOG Study 8795 The adverse reaction profile of TICE BCG was similar in the Nijmegen study. 8 Study arm TICE BCG (N=222) MMC (N=220) Adverse event All Grades Grade ≥3 All Grades Grade ≥3 Dysuria 115 (52%) 6 (3%) 77 (35%) 5 (2%) Urgency/frequency 112 (50%) 5 (2%) 63 (29%) 7 (3%) Hematuria 85 (38%) 6 (3%) 56 (25%) 5 (2%) Flu-like symptoms 54 (24%) 1 (<1%) 29 (13%) 0 Fever 37 (17%) 1 (<1%) 7 (3%) 0 Pain (not specified) 37 (17%) 4 (2%) 22 (10%) 1 (<1%) Hemorrhagic cystitis 19 (9%) 3 (1%) 10 (5%) 0 Chills 19 (9%) 0 2 (1%) 0 Bladder cramps 18 (8%) 0 9 (4%) 0 Nausea 16 (7%) 0 12 (5%) 0 Incontinence 8 (4%) 0 3 (1%) 0 Myalgia/arthralgia 7 (3%) 0 0 0 Diaphoresis 7 (3%) 0 1 (<1%) 0 Rash 6 (3%) 1 (<1%) 16 (7%) 2 (1%)"],"contraindications":["CONTRAINDICATIONS Immunosuppressed Patients TICE ® BCG should not be used in immunosuppressed patients with congenital or acquired immune deficiencies, whether due to concurrent disease (e.g., AIDS, leukemia, lymphoma) cancer therapy (e.g., cytotoxic drugs, radiation), or immunosuppressive therapy (e.g., corticosteroids). Patients with Increased Risk of BCG Infection Treatment should be postponed until resolution of a concurrent febrile illness, urinary tract infection, or gross hematuria. Seven to 14 days should elapse before BCG is administered following biopsy, TUR, or traumatic catheterization. Active Tuberculosis TICE BCG should not be administered to persons with active tuberculosis. Active tuberculosis should be ruled out in individuals who are PPD positive before starting treatment with TICE BCG."],"drug_interactions":["Drug Interaction Drug combinations containing immunosuppressants and/or bone marrow depressants and/or radiation interfere with the development of the immune response and should not be used in combination with TICE BCG. Antimicrobial therapy for other infections may interfere with the effectiveness of TICE BCG. There are no data to suggest that the acute, local urinary tract toxicity common with BCG is due to mycobacterial infection, and antituberculosis drugs (e.g., isoniazid) should not be used to prevent or treat the local, irritative toxicities of TICE BCG."],"general_precautions":["General TICE ® BCG contains live mycobacteria and should be prepared and handled using aseptic technique (see DOSAGE AND ADMINISTRATION, Preparation of Agent section). BCG infections have been reported in health care workers preparing BCG for administration. Needle stick injuries should be avoided during the handling and mixing of TICE BCG. Nosocomial infections have been reported in patients receiving parenteral drugs which were prepared in areas in which BCG was prepared. 4 BCG is capable of dissemination when administered by intravesical route, and serious reactions, including fatal infections, have been reported in patients receiving intravesical BCG. 3 Care should be taken not to traumatize the urinary tract or to introduce contaminants into the urinary system. Seven to 14 days should elapse before TICE BCG is administered following TUR, biopsy, or traumatic catheterization. TICE BCG should be administered with caution to persons in groups at high risk for HIV infection."],"storage_and_handling":["STORAGE The intact vials of TICE ® BCG should be stored refrigerated, at 2–8°C (36–46°F). This agent contains live bacteria and should be protected from direct sunlight. The product should not be used after the expiration date printed on the label."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY TICE ® BCG induces a granulomatous reaction at the local site of administration. Intravesical TICE BCG has been used as a therapy for, and prophylaxis against, recurrent tumors in patients with carcinoma in situ (CIS) of the urinary bladder, and to prevent recurrence of Stage TaT1 papillary tumors of the bladder at high risk of recurrence. The precise mechanism of action is unknown."],"indications_and_usage":["INDICATIONS AND USAGE TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence. TICE BCG is not indicated for papillary tumors of stages higher than T1."],"clinical_studies_table":["<table width=\"90%\"><caption>Table 1: The Response of Patients With CIS Bladder Cancer in 6 IND Studies</caption><col width=\"25%\" align=\"left\" valign=\"top\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><thead><tr><th/><th valign=\"top\">Entered</th><th valign=\"top\">Evaluable</th><th valign=\"top\">CR</th><th valign=\"top\">CRNC</th><th valign=\"top\">Overall response</th></tr></thead><tbody><tr><td>No. (%) of patients</td><td>153</td><td>119 (78%)</td><td>54 (46%)</td><td>36 (30%)</td><td>90 (76%)</td></tr></tbody></table>","<table width=\"90%\" ID=\"tableII\"><caption>Table 2: Follow-up Response of Patients With CIS Bladder Cancer in 6 IND Studies</caption><col width=\"30%\" align=\"left\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"25%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><thead><tr><th colspan=\"5\" align=\"center\"><content styleCode=\"underline\">1989 Status of 90 Responders (CR or CRNC)</content></th></tr><tr><th>Response</th><th><content styleCode=\"underline\">1987/CR</content> n=54</th><th><content styleCode=\"underline\">1987/CRNC</content> n=36</th><th><content styleCode=\"underline\">1987 Response</content> n=90</th><th>Percent</th></tr></thead><tbody><tr><td>CR</td><td>30</td><td>15</td><td>45</td><td>50</td></tr><tr><td>CRNC</td><td> 0</td><td> 0</td><td> 0</td><td> 0</td></tr><tr><td>Unrelated deaths</td><td> 6</td><td> 6</td><td>12</td><td>13</td></tr><tr><td>Failure</td><td>18</td><td>15</td><td>33</td><td>37</td></tr></tbody></table>","<table width=\"80%\" ID=\"tableIII\"><caption>Table 3: Results of SWOG Study 8795</caption><col width=\"50%\" align=\"left\" valign=\"top\"/><col width=\"25%\" align=\"center\" valign=\"top\"/><col width=\"25%\" align=\"right\" valign=\"top\"/><thead><tr><th/><th>TICE BCG Arm N=191</th><th>MMC Arm N=186</th></tr></thead><tbody><tr><td>Estimated disease-free survival at 2 years</td><td>57%</td><td>45%</td></tr><tr><td>95% Confidence Interval (CI)</td><td>(50%, 65%)</td><td>(38%, 53%)</td></tr></tbody></table>","<table width=\"90%\" ID=\"tableiv\"><caption>Table 4: Results of Nijmegen Study</caption><col width=\"40%\" align=\"left\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><col width=\"20%\" align=\"center\" valign=\"top\"/><thead><tr><th/><th>TICE BCG Arm N=117</th><th>BCG-RIVM Arm N=134</th><th>MMC Arm N=136</th></tr></thead><tbody><tr><td>Estimated disease-free survival at 2 years</td><td>53%</td><td>62%</td><td>64%</td></tr><tr><td>95% Confidence Interval (CI)</td><td>(44%, 64%)</td><td>(53%, 72%)</td><td>(55%, 74%)</td></tr></tbody></table>"],"adverse_reactions_table":["<table width=\"100%\" ID=\"tableV\"><caption>Table 5: Summary of Adverse Effects Seen in 674 Patients With Superficial Bladder Cancer, Including 153 With Carcinoma in Situ</caption><col width=\"25%\" align=\"left\" valign=\"bottom\"/><col width=\"10%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"25%\" align=\"left\" valign=\"bottom\"/><col width=\"10%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><thead><tr><th colspan=\"3\" align=\"center\"><content styleCode=\"underline\">Percent of patients</content></th><th colspan=\"3\" align=\"center\"><content styleCode=\"underline\">Percent of patients</content></th></tr><tr><th align=\"center\">Adverse event</th><th>N</th><th>Overall (Grade &#x2265;3)</th><th align=\"center\">Adverse event</th><th>N</th><th>Overall (Grade &#x2265;3)</th></tr></thead><tbody><tr><td>Dysuria</td><td>401</td><td> 60% (11%)</td><td>Arthritis/myalgia</td><td>18</td><td>3% (&lt;1%)</td></tr><tr><td>Urinary frequency</td><td>272</td><td>40% (7%)</td><td>Headache/dizziness</td><td>16</td><td>2%(0) </td></tr><tr><td>Flu-like syndrome</td><td>224</td><td>33% (9%)</td><td>Urinary incontinence</td><td>16</td><td>2% (0) </td></tr><tr><td>Hematuria</td><td>175</td><td>26% (7%)</td><td>Anorexia/weight loss</td><td>15</td><td>2% (&lt;1%)</td></tr><tr><td>Fever</td><td>134</td><td>20% (8%)</td><td>Urinary debris</td><td>15</td><td>2% (&lt;1%)</td></tr><tr><td>Malaise/fatigue</td><td> 50</td><td>7% (0) </td><td>Allergy</td><td>14</td><td>2% (&lt;1%)</td></tr><tr><td>Cystitis</td><td> 40</td><td> 6% (2%)</td><td>Cardiac (unclassified)</td><td>13</td><td>2% (1%) </td></tr><tr><td>Urgency</td><td> 39</td><td> 6% (1%)</td><td>Genital inflammation/</td><td/><td/></tr><tr><td>Nocturia</td><td> 30</td><td> 5% (1%)</td><td>abscess</td><td>12</td><td>2% (&lt;1%)</td></tr><tr><td>Cramps/pain</td><td> 27</td><td> 4% (1%)</td><td>Respiratory (unclassified)</td><td>11</td><td>2% (&lt;1%)</td></tr><tr><td>Rigors</td><td> 22</td><td> 3% (1%)</td><td>Urinary tract infection</td><td>10</td><td>2% (1%) </td></tr><tr><td>Nausea/vomiting</td><td> 20</td><td> 3% (&lt;1%)</td><td>Abdominal pain</td><td>10</td><td>2% (1%) </td></tr></tbody></table>","<table width=\"100%\"><caption>Table 6: Most Common Adverse Reactions in SWOG Study 8795<footnote>The adverse reaction profile of TICE BCG was similar in the Nijmegen study.<sup>8</sup></footnote></caption><col width=\"40%\" align=\"left\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><col width=\"15%\" align=\"center\" valign=\"bottom\"/><thead><tr><th/><th colspan=\"4\">Study arm</th></tr><tr><th/><th colspan=\"2\">TICE BCG (N=222)</th><th colspan=\"2\">MMC (N=220)</th></tr><tr><th>Adverse event</th><th>All Grades</th><th>Grade &#x2265;3</th><th>All Grades</th><th>Grade &#x2265;3</th></tr></thead><tbody><tr><td>Dysuria</td><td>115 (52%)</td><td>6 (3%)</td><td>77 (35%)</td><td> 5 (2%)</td></tr><tr><td>Urgency/frequency</td><td>112 (50%)</td><td>5 (2%)</td><td>63 (29%)</td><td>7 (3%)</td></tr><tr><td>Hematuria</td><td> 85 (38%)</td><td>6 (3%)</td><td>56 (25%)</td><td>5 (2%)</td></tr><tr><td>Flu-like symptoms</td><td> 54 (24%)</td><td> 1 (&lt;1%)</td><td>29 (13%)</td><td>0</td></tr><tr><td>Fever</td><td> 37 (17%)</td><td> 1 (&lt;1%)</td><td>7 (3%)</td><td>0</td></tr><tr><td>Pain (not specified)</td><td> 37 (17%)</td><td>4 (2%)</td><td>22 (10%)</td><td> 1 (&lt;1%)</td></tr><tr><td>Hemorrhagic cystitis</td><td>19 (9%)</td><td>3 (1%)</td><td>10 (5%) </td><td>0</td></tr><tr><td>Chills</td><td>19 (9%)</td><td>0 </td><td>2 (1%)</td><td>0</td></tr><tr><td>Bladder cramps</td><td>18 (8%)</td><td>0 </td><td>9 (4%)</td><td>0</td></tr><tr><td>Nausea</td><td>16 (7%)</td><td>0 </td><td>12 (5%) </td><td>0</td></tr><tr><td>Incontinence</td><td> 8 (4%)</td><td>0 </td><td>3 (1%)</td><td>0</td></tr><tr><td>Myalgia/arthralgia</td><td> 7 (3%)</td><td>0 </td><td>0 </td><td>0</td></tr><tr><td>Diaphoresis</td><td> 7 (3%)</td><td>0 </td><td> 1 (&lt;1%)</td><td>0</td></tr><tr><td>Rash</td><td> 6 (3%)</td><td> 1 (&lt;1%)</td><td>16 (7%) </td><td>2 (1%)</td></tr></tbody></table>"],"information_for_patients":["Information for Patients TICE BCG is retained in the bladder for 2 hours and then voided. Patients should void while seated in order to avoid splashing of urine. For the 6 hours after treatment, urine voided should be disinfected for 15 minutes with an equal volume of household bleach before flushing. Patients should be instructed to increase fluid intake in order to \"flush\" the bladder in the hours following BCG treatment. Patients may experience burning with the first void after treatment. Patients should be attentive to side effects, such as fever, chills, malaise, flu-like symptoms, or increased fatigue. If the patient experiences severe urinary side effects, such as burning or pain on urination, urgency, frequency of urination, blood in urine, or other symptoms such as joint pain, cough, or skin rash, the physician should be notified."],"spl_unclassified_section":["Post-marketing Experience The following adverse reactions have been identified during post-approval use of TICE BCG. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Immune System Disorders : hemophagocytic lymphohistiocytosis (HLH).","Manufactured for: Merck Sharp & Dohme LLC Rahway, NJ 07065, USA Manufactured by: Merck Teknika LLC, Durham, NC 27712, USA U.S. License No. 1747 For patent information: www.msd.com/research/patent TICE is a registered trademark of The Board of Trustees of the University of Illinois, used under the license of Merck Teknika LLC, Durham, NC, USA. Copyright © 2021-2026 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. Revised: 2/2026 uspi-v914-pwi-2602r013"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The dose for the intravesical treatment of carcinoma in situ and for the prophylaxis of recurrent papillary tumors consists of 1 vial of TICE ® BCG suspended in 50 mL preservative-free saline. Do not inject subcutaneously or intravenously. Preparation of Agent The preparation of the TICE BCG suspension should be done using aseptic technique. To avoid cross-contamination, parenteral drugs should not be prepared in areas where BCG has been prepared. A separate area for the preparation of the TICE BCG suspension is recommended. All equipment, supplies, and receptacles in contact with TICE BCG should be handled and disposed of as biohazardous. The pharmacist or individual responsible for mixing the agent should wear gloves and take precautions to avoid contact of BCG with broken skin. If preparation cannot be performed in a biocontainment hood, then a mask and gown should be worn to avoid inhalation of BCG organisms and inadvertent exposure to broken skin. Draw 1 mL of sterile, preservative-free saline (0.9% Sodium Chloride Injection USP) at 4–25°C into a small syringe (e.g., 3 mL) and add to 1 vial of TICE BCG to resuspend. Ensure that the needle is inserted through the center of the rubber stopper of the vial. Gently swirl the vial until a homogenous suspension is obtained. Avoid forceful agitation which may cause clumping of the mycobacteria. Dilute the cloudy TICE BCG suspension in sterile, preservative-free saline to a final volume of 50 mL. Mix the suspension gently prior to intravesical instillation. The reconstituted TICE BCG should be kept refrigerated (2–8°C), protected from exposure to direct sunlight, and used within 2 hours. Discard unused portion. Note: DO NOT filter the contents of the TICE BCG vial. Precautions should be taken to avoid exposing the TICE BCG to direct sunlight. Bacteriostatic solutions must be avoided. In addition, use only sterile, preservative-free saline, 0.9% Sodium Chloride Injection USP as diluent. Treatment and Schedule Allow 7 to 14 days to elapse after bladder biopsy before TICE BCG is administered. Patients should not drink fluids for 4 hours before treatment and should empty their bladder prior to TICE BCG administration. The reconstituted TICE BCG is instilled into the bladder by gravity flow via the catheter. After instillation of the TICE BCG suspension is complete, remove the catheter. The TICE BCG is retained in the bladder for 2 hours and then voided. Patients unable to retain the suspension for 2 hours should be allowed to void sooner, if necessary. While the BCG is retained in the bladder, the patient ideally should be repositioned from left side to right side and also should lie upon the back and the abdomen, changing these positions every 15 minutes to maximize bladder surface exposure to the agent. A standard treatment schedule consists of 1 intravesical instillation per week for 6 weeks. This schedule may be repeated once if tumor remission has not been achieved and if the clinical circumstances warrant. Thereafter, intravesical TICE BCG administration should continue at approximately monthly intervals for at least 6 to 12 months. There are no data to support the interchangeability of BCG LIVE products."],"spl_product_data_elements":["TICE BCG BACILLUS CALMETTE-GUERIN BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN GLYCERIN ASPARAGINE CITRIC ACID MONOHYDRATE POTASSIUM PHOSPHATE, UNSPECIFIED FORM MAGNESIUM SULFATE, UNSPECIFIED FORM LACTOSE, UNSPECIFIED FORM FERRIC AMMONIUM CITRATE"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 50 mL Vial Carton NDC 0052-0602-02 BCG LIVE (for Intravesical Use) TICE ® BCG Rx only Single-Dose Vial Principal Display Panel - 50 mL Vial Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility TICE BCG has not been evaluated for its carcinogenic, mutagenic potentials, or impairment of fertility."]},"tags":[],"safety":{"boxedWarnings":["WARNING TICE ® BCG contains live, attenuated mycobacteria. Because of the potential risk for transmission, prepare, handle, and dispose of TICE ® BCG as a biohazard material (see PRECAUTIONS and DOSAGE AND ADMINISTRATION sections). BCG infections have been reported in health care workers, primarily from exposures resulting from accidental needle sticks or skin lacerations during the preparation of BCG for administration. Nosocomial infections have been reported in patients receiving parenteral drugs that were prepared in areas in which BCG was reconstituted. BCG is capable of dissemination when administered by the intravesical route, and serious infections, including fatal infections, have been reported in patients receiving intravesical BCG (see WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS sections)."],"safetySignals":[{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"Reported 425 times"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"Reported 411 times"},{"date":"","signal":"DISSEMINATED BACILLUS CALMETTE-GUERIN INFECTION","source":"FDA FAERS","actionTaken":"Reported 333 times"},{"date":"","signal":"BLADDER CANCER RECURRENT","source":"FDA FAERS","actionTaken":"Reported 286 times"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"Reported 264 times"},{"date":"","signal":"PRODUCT AVAILABILITY ISSUE","source":"FDA FAERS","actionTaken":"Reported 237 times"},{"date":"","signal":"PRODUCT DOSE OMISSION","source":"FDA FAERS","actionTaken":"Reported 178 times"},{"date":"","signal":"BOVINE TUBERCULOSIS","source":"FDA FAERS","actionTaken":"Reported 145 times"},{"date":"","signal":"DYSURIA","source":"FDA FAERS","actionTaken":"Reported 115 times"},{"date":"","signal":"HAEMATURIA","source":"FDA FAERS","actionTaken":"Reported 115 times"}],"drugInteractions":[{"drug":"immunosuppressants and/or bone marrow depressants and/or radiation","action":"Avoid","effect":"interfere with the development of the immune response"},{"drug":"antimicrobial therapy","action":"Monitor","effect":"interfere with the effectiveness of TICE BCG"},{"drug":"antituberculosis drugs (e.g., isoniazid)","action":"Avoid","effect":"prevent or treat the local, irritative toxicities of TICE BCG"}],"commonSideEffects":[{"effect":"Dysuria","drugRate":"60%","severity":"mild","_validated":true},{"effect":"Arthritis/myalgia","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Urinary frequency","drugRate":"40%","severity":"mild","_validated":true},{"effect":"Headache/dizziness","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Flu-like syndrome","drugRate":"33%","severity":"mild","_validated":true},{"effect":"Urinary incontinence","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Hematuria","drugRate":"26%","severity":"mild","_validated":true},{"effect":"Anorexia/weight loss","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Fever","drugRate":"20%","severity":"mild","_validated":true},{"effect":"Urinary debris","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Malaise/fatigue","drugRate":"7%","severity":"mild","_validated":true},{"effect":"Allergy","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Cystitis","drugRate":"6%","severity":"mild","_validated":true},{"effect":"Cardiac (unclassified)","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Urgency","drugRate":"6%","severity":"mild","_validated":true},{"effect":"Genital inflammation/abscess","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Cramps/pain","drugRate":"4%","severity":"mild","_validated":true},{"effect":"Respiratory (unclassified)","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Rigors","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Urinary tract infection","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Nausea/vomiting","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Abdominal pain","drugRate":"2%","severity":"mild","_validated":true}],"contraindications":["Immunosuppressed Patients TICE BCG should not be used in immunosuppressed patients with congenital or acquired immune deficiencies, whether due to concurrent disease (e.g., AIDS, leukemia, lymphoma) cancer therapy (e.g., cytotoxic drugs, radiation), or immunosuppressive therapy (e.g., corticosteroids).","Patients with Increased Risk of BCG Infection Treatment should be postponed until resolution of a concurrent febrile illness, urinary tract infection, or gross hematuria. Seven to 14 days should elapse before BCG is administered following biopsy, TUR, or traumatic catheterization.","Active Tuberculosis TICE BCG should not be administered to persons with active tuberculosis. Active tuberculosis should be ruled out in individuals who are PPD positive before starting treatment with TICE BCG."],"specialPopulations":{"Pregnancy":"Pregnancy Animal reproduction studies have not been conducted with TICE BCG. It is also not known whether TICE BCG can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. TICE BCG should not be given to a pregnant woman except when clearly needed. Women should be advised not to become pregnant while on therapy.","Geriatric use":"Of the total number of subjects in clinical studies of TICE BCG, the average age was 66 years old. No overall difference in safety or effectiveness was observed between older and younger subjects. Other reported clinical experience has not identified differences in response between elderly and younger patients, but greater sensitivity of some older individuals to BCG cannot be ruled out.","Paediatric use":"Safety and effectiveness of TICE BCG for the treatment of superficial bladder cancer in pediatric patients have not been established.","Nursing mothers":"It is not known whether TICE BCG is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from TICE BCG in nursing infants, it is advisable to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."}},"trials":[],"_whoEML":{"listed":true,"source":"WHO EML"},"aliases":[],"company":"Pfizer","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$157.0827/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$57,335","description":"BCG (TICE STRAIN) VIAL","retrievedDate":"2026-04-07"}],"_recalls":[{"date":"20120822","reason":"Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. FDA environmental sampling revealed the presence of microorganisms and fungal growth in the clean room where sterile products were prepared.","classification":"Class II"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=bcg","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:43:23.456363+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:43:29.218188+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:43:23.527805+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bcg","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:43:29.658421+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:22.037376+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:22.037404+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING TICE ® BCG contains live, attenuated mycobacteria. Because of the potential risk for transmission, prepare, handle, and dispose of TICE ® BCG as a biohazard material (see PRECAUTIONS and DOSAGE AND ADMINISTRATION sections). BCG infections have been reported in health care workers, primarily from exposures resulting from accidental needle sticks or skin lacerations during the preparation of BCG for administration. Nosocomial infections have been reported in patients receiving parenteral d","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:22.037411+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2108905/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:43:30.357075+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"BLA102821","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:43:22.037414+00:00"}},"allNames":"tice bcg","offLabel":[],"timeline":[],"_dailymed":{"setId":"a83f0b99-9038-4c5a-aaac-8792b32838fe","title":"BCG VACCINE (BACILLUS CALMETTE-GUERIN SUBSTRAIN TICE LIVE ANTIGEN) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [MERCK SHARP & DOHME LLC]","labeler":""},"aiSummary":"BCG is a marketed drug by Pfizer Inc. for the treatment of bladder cancer. It is used to treat superficial bladder cancer, carcinoma in situ (CIS) of the urinary bladder, and non-muscle invasive bladder cancer (NMIBC). BCG is a vaccine-derived therapy that works by stimulating the immune system to attack cancer cells. It has been widely used and has a significant commercial presence. The drug has undergone numerous clinical trials and has been the subject of many publications. BCG's revenue is substantial, with $63.6 billion in revenue.","brandName":"Tice Bcg","ecosystem":[],"isGeneric":true,"mechanism":{"target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","novelty":"Best-in-class","modality":"Vaccine-derived therapy","drugClass":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","explanation":"","oneSentence":"","technicalDetail":"BCG works by inducing a cell-mediated immune response against cancer cells, which helps to prevent the recurrence of bladder cancer. The exact mechanism of action is not fully understood, but it is thought to involve the activation of immune cells such as T-cells and macrophages. BCG has been shown to be effective in treating a range of bladder cancer subtypes, including superficial and non-muscle invasive disease."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"192,700","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"83,000","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=bcg","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=bcg","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=bcg","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":6,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":7,"url":"https://www.whocc.no/atc_ddd_index/","fields":["classification"],"source":"WHO ATC/DDD Index"},{"id":8,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:43:47.071345+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"rBCG","company":"Serum Institute of India","advantage":"Enhanced immunogenicity and safety compared to traditional BCG formulations"},{"name":"TICE BCG","company":"Merck & Co.","advantage":"None mentioned, but considered a competitor due to FDA authorization of rBCG as an alternative"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"bcg","indications":{"approved":[{"name":"Treatment of bladder cancer (superficial)","regulator":"FDA"},{"name":"Treatment of carcinoma in situ (CIS) of the urinary bladder","regulator":"FDA"},{"name":"Treatment of non-muscle invasive bladder cancer (NMIBC)","regulator":"FDA"},{"name":"Treatment of high-grade non-muscle invasive bladder cancer (NMIBC)","regulator":"FDA"},{"name":"Treatment of high-risk non-muscle invasive bladder cancer (NMIBC)","regulator":"FDA"},{"name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)","regulator":"FDA"},{"name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with high-grade tumor","regulator":"FDA"},{"name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with high-risk tumor","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC))","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","regulator":"FDA"},{"name":"Treatment of superficial bladder cancer (stage Ta, T1, Tis, high-grade, high-risk, carcinoma in situ, high-grade tumor, high-risk tumor, non-muscle invasive, non-muscle invasive bladder cancer, non-muscle invasive bladder cancer (NMIBC), non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-risk tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor, non-muscle invasive bladder cancer (NMIBC) with high-grade tumor)","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04164082","phase":"PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-03-18","conditions":"Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8","enrollment":161},{"nctId":"NCT07222488","phase":"PHASE1, PHASE2","title":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-09","conditions":"Bladder Cancer, Urinary Bladder Neoplasms","enrollment":45},{"nctId":"NCT06800963","phase":"PHASE1, PHASE2","title":"ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-10-15","conditions":"NMIBC","enrollment":40},{"nctId":"NCT07495072","phase":"NA","title":"Early vs Delayed Intravesical Blad-Care During BCG Therapy","status":"RECRUITING","sponsor":"BLAD-HYA Group","startDate":"2025-11-03","conditions":"Urinary Bladder Neoplasms, BCG-Induced Cystitis","enrollment":56},{"nctId":"NCT06833073","phase":"PHASE2","title":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-11","conditions":"Urinary Bladder Neoplasms, Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ","enrollment":308},{"nctId":"NCT03091660","phase":"PHASE3","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-02-24","conditions":"Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma","enrollment":1000},{"nctId":"NCT02138734","phase":"PHASE1, PHASE2","title":"A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2014-07-21","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":596},{"nctId":"NCT05037279","phase":"PHASE3","title":"Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)","status":"RECRUITING","sponsor":"Verity Pharmaceuticals Inc.","startDate":"2024-04-24","conditions":"Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence","enrollment":540},{"nctId":"NCT06257212","phase":"PHASE4","title":"Live Vaccines and Innate Immune Training in COPD.","status":"COMPLETED","sponsor":"Josefin Eklöf","startDate":"2024-02-28","conditions":"Trained Innate Immunity, COPD","enrollment":60},{"nctId":"NCT05714202","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-23","conditions":"Bladder Cancer","enrollment":1135},{"nctId":"NCT07483970","phase":"PHASE1","title":"A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2026-03-30","conditions":"High Risk Non-muscle Invasive Bladder Cancer","enrollment":18},{"nctId":"NCT07480356","phase":"PHASE3","title":"Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Protara Therapeutics","startDate":"2026-05","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":284},{"nctId":"NCT05547464","phase":"PHASE1, PHASE2","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2023-07-31","conditions":"Tuberculosis","enrollment":497},{"nctId":"NCT07322263","phase":"PHASE2","title":"Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Michael A. O'Donnell","startDate":"2026-04-01","conditions":"Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), Urothelial Carcinoma","enrollment":174},{"nctId":"NCT06211764","phase":"PHASE3","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-09","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":272},{"nctId":"NCT03258593","phase":"PHASE1","title":"Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-07","conditions":"Urinary Bladder Neoplasms","enrollment":15},{"nctId":"NCT07342517","phase":"PHASE3","title":"A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy","status":"WITHDRAWN","sponsor":"Relmada Therapeutics, Inc.","startDate":"2026-06-30","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder","enrollment":0},{"nctId":"NCT04452591","phase":"PHASE3","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","status":"ACTIVE_NOT_RECRUITING","sponsor":"CG Oncology, Inc.","startDate":"2020-10-27","conditions":"Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer","enrollment":190},{"nctId":"NCT07474519","phase":"PHASE4","title":"Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2026-02-26","conditions":"Non-Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT05316155","phase":"PHASE1, PHASE2","title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-04-11","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":235},{"nctId":"NCT04640623","phase":"PHASE2","title":"A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-18","conditions":"Urinary Bladder Neoplasms","enrollment":220},{"nctId":"NCT07468851","phase":"PHASE1, PHASE2","title":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2026-06-10","conditions":"High-risk Non-muscle-invasive Bladder Cancer","enrollment":180},{"nctId":"NCT05843448","phase":"PHASE1","title":"IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-04-19","conditions":"High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8","enrollment":30},{"nctId":"NCT06919965","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-09-10","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":220},{"nctId":"NCT05947890","phase":"PHASE2","title":"Evaluating the Safety and Immunogenicity of MTBVAC","status":"RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2024-01-30","conditions":"HIV I Infection, Tuberculosis","enrollment":276},{"nctId":"NCT07206225","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-06","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":294},{"nctId":"NCT07464145","phase":"PHASE3","title":"A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Relmada Therapeutics, Inc.","startDate":"2026-06","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder","enrollment":393},{"nctId":"NCT05943106","phase":"PHASE3","title":"BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-11","conditions":"Non-Muscle- Invasive Bladder Cancer","enrollment":100},{"nctId":"NCT06050356","phase":"PHASE1","title":"First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b","status":"ACTIVE_NOT_RECRUITING","sponsor":"Statens Serum Institut","startDate":"2024-03-14","conditions":"Healthy","enrollment":140},{"nctId":"NCT06443944","phase":"","title":"An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG","status":"AVAILABLE","sponsor":"CG Oncology, Inc.","startDate":"","conditions":"Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer","enrollment":""},{"nctId":"NCT07447999","phase":"","title":"Multimodal Deep Learning Model for Predicting the Apnea-Hypopnea Index in Obstructive Sleep","status":"RECRUITING","sponsor":"Fu Jen Catholic University","startDate":"2025-09-05","conditions":"Obstructive Sleep Apnea (OSA), Polysomnography","enrollment":150},{"nctId":"NCT07000084","phase":"PHASE3","title":"Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-07-17","conditions":"Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":330},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT01778569","phase":"","title":"The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2013-01-22","conditions":"Metabolic Disease, Cardiovascular Disease, Inflammation","enrollment":386},{"nctId":"NCT07445308","phase":"PHASE1, PHASE2","title":"The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.","status":"NOT_YET_RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2026-03-12","conditions":"NMIBC","enrollment":120},{"nctId":"NCT04701151","phase":"PHASE4","title":"NORTH-REG Dwell-Time Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jørgen Bjerggaard Jensen","startDate":"2021-02-03","conditions":"Side Effect of Drug","enrollment":314},{"nctId":"NCT05538663","phase":"PHASE3","title":"Intravesical BCG vs GEMDOCE in NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-02-07","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":870},{"nctId":"NCT05644041","phase":"PHASE2","title":"Intravesical Gem/Doce in Patients With NMIBC","status":"RECRUITING","sponsor":"University of Arizona","startDate":"2023-03-01","conditions":"Urinary Bladder Cancer","enrollment":25},{"nctId":"NCT06579157","phase":"","title":"Pressure-Sensing Mattresses and Mechanical Ventilation Weaning in Neonatal","status":"RECRUITING","sponsor":"Fu Jen Catholic University","startDate":"2024-11-10","conditions":"Bronchopulmonary Dysplasia","enrollment":60},{"nctId":"NCT04172675","phase":"PHASE2","title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-02-28","conditions":"Urinary Bladder Neoplasms","enrollment":107},{"nctId":"NCT07424287","phase":"PHASE3","title":"A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"NMIBC","enrollment":236},{"nctId":"NCT05710848","phase":"PHASE1, PHASE2","title":"A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer","status":"RECRUITING","sponsor":"SURGE Therapeutics","startDate":"2023-07-11","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":75},{"nctId":"NCT06972615","phase":"PHASE2","title":"Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy","status":"NOT_YET_RECRUITING","sponsor":"BLATAM","startDate":"2026-04-01","conditions":"Non Muscle Invasive Bladder Cancer","enrollment":37},{"nctId":"NCT05591339","phase":"PHASE4","title":"Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bandim Health Project","startDate":"2023-12-01","conditions":"Diabetes Mellitus, BCG Vaccination Reaction","enrollment":200},{"nctId":"NCT06026332","phase":"","title":"ADSTILADRIN Early Utilization and Outcomes in the Real World Setting","status":"TERMINATED","sponsor":"Ferring Pharmaceuticals","startDate":"2023-09-15","conditions":"Bladder Cancer","enrollment":202},{"nctId":"NCT04658680","phase":"PHASE4","title":"Can BCG Vaccination at First Health-facility Contact Reduce Early Infant Mortality?","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bandim Health Project","startDate":"2021-02-25","conditions":"Infant Mortality, BCG","enrollment":22800},{"nctId":"NCT06245603","phase":"NA","title":"A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2024-12-20","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":200},{"nctId":"NCT04564781","phase":"","title":"Predicting BCG Response","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2020-09-18","conditions":"Bladder Cancer","enrollment":400},{"nctId":"NCT04752722","phase":"PHASE1, PHASE2","title":"LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve","status":"RECRUITING","sponsor":"enGene, Inc.","startDate":"2021-04-22","conditions":"Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":350},{"nctId":"NCT04453293","phase":"PHASE3","title":"Immunization With BCG Vaccine to Prevent Tuberculosis Infection","status":"TERMINATED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2021-12-01","conditions":"Tuberculosis Infection","enrollment":16},{"nctId":"NCT04165317","phase":"PHASE3","title":"A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-12-30","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":1068},{"nctId":"NCT07283835","phase":"PHASE2","title":"Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin","status":"RECRUITING","sponsor":"Lepu Biopharma Co., Ltd.","startDate":"2025-12-04","conditions":"Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer","enrollment":16},{"nctId":"NCT04630730","phase":"PHASE2","title":"Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2022-06-24","conditions":"Bladder Cancer","enrollment":46},{"nctId":"NCT07307456","phase":"PHASE2","title":"Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2025-12-08","conditions":"Bladder Cancer","enrollment":31},{"nctId":"NCT06747455","phase":"PHASE3","title":"BCG for Therapeutic Use Phase Ⅲ Clinical Trial","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-04-08","conditions":"BCG","enrollment":438},{"nctId":"NCT05537038","phase":"PHASE1","title":"Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2023-04-18","conditions":"Tuberculosis","enrollment":120},{"nctId":"NCT03711032","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-24","conditions":"High-risk Non-muscle Invasive Bladder Cancer","enrollment":1397},{"nctId":"NCT05327647","phase":"PHASE2","title":"A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2022-06-23","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":160},{"nctId":"NCT06845358","phase":"PHASE1","title":"Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy Humans","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-11-26","conditions":"Tuberculosis","enrollment":0},{"nctId":"NCT05024773","phase":"PHASE3","title":"Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)","status":"RECRUITING","sponsor":"Fidia Farmaceutici s.p.a.","startDate":"2022-12-29","conditions":"Bladder Carcinoma in Situ (CIS)","enrollment":112},{"nctId":"NCT05592223","phase":"PHASE1","title":"Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-06","conditions":"Tuberculosis","enrollment":20},{"nctId":"NCT04507126","phase":"PHASE2","title":"A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-03-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT06670755","phase":"NA","title":"ID93/GLA-SE Vaccination + BCG Challenge","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2024-12-18","conditions":"Tuberculosis","enrollment":48},{"nctId":"NCT02081326","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2015-06","conditions":"Diabetes Mellitus, Type One, Diabetes Mellitus, Type I, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05180591","phase":"PHASE2","title":"Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-03-22","conditions":"Diabetes Mellitus, Type 1, Diabetes type1, Autoimmune Diabetes","enrollment":150},{"nctId":"NCT05866536","phase":"PHASE2","title":"Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-05-04","conditions":"Diabetes Mellitus, Type 1 Diabetes, Diabetes type1","enrollment":100},{"nctId":"NCT06148025","phase":"PHASE4","title":"Antibiotics and Vaccine Immune Responses Study","status":"RECRUITING","sponsor":"South Australian Health and Medical Research Institute","startDate":"2023-11-23","conditions":"Vaccine Response Impaired","enrollment":348},{"nctId":"NCT07268339","phase":"PHASE3","title":"A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.","status":"NOT_YET_RECRUITING","sponsor":"The Christie NHS Foundation Trust","startDate":"2025-12-01","conditions":"High-Risk Non-Muscle Invasive Bladder Cancer","enrollment":328},{"nctId":"NCT05768347","phase":"PHASE1","title":"Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-10","conditions":"Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma","enrollment":9},{"nctId":"NCT03528694","phase":"PHASE3","title":"Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-05-14","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":1018},{"nctId":"NCT03945162","phase":"PHASE2","title":"Intravesical Photodynamic Therapy (\"PDT\") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Patients","status":"RECRUITING","sponsor":"Theralase® Technologies Inc.","startDate":"2019-08-30","conditions":"Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Unresponsive/Intolerant to BCG","enrollment":90},{"nctId":"NCT04412070","phase":"","title":"Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients","status":"TERMINATED","sponsor":"Hopital Foch","startDate":"2021-07-30","conditions":"Bladder Cancer","enrollment":20},{"nctId":"NCT02625961","phase":"PHASE2","title":"Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-02-10","conditions":"Bladder Cancer","enrollment":296},{"nctId":"NCT07231809","phase":"NA","title":"Hyperthermic Intravesical Chemotherapy (HIVEC) in BCG-Non-Responsive High-Grade NMIBC Patients","status":"NOT_YET_RECRUITING","sponsor":"AC.TA. S.r.l.","startDate":"2026-01-15","conditions":"Non Muscle Invasive Bladder Cancer, Bladder Cancer, Carcinoma in Situ of Bladder","enrollment":50},{"nctId":"NCT06246851","phase":"NA","title":"BCG Revaccination Study in Diabetic and Non-Diabetic Adults","status":"ENROLLING_BY_INVITATION","sponsor":"University of Oxford","startDate":"2024-04-03","conditions":"Tuberculosis","enrollment":36},{"nctId":"NCT05672615","phase":"","title":"Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2023-03-21","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":42},{"nctId":"NCT04386746","phase":"PHASE2","title":"Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-07-29","conditions":"Urothelial Carcinoma Bladder, Bladder Cancer","enrollment":27},{"nctId":"NCT03504163","phase":"PHASE2","title":"Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-27","conditions":"Bladder Cancer","enrollment":45},{"nctId":"NCT03933826","phase":"","title":"CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2019-07-09","conditions":"Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer","enrollment":570},{"nctId":"NCT06929286","phase":"PHASE3","title":"A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-04-11","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":125},{"nctId":"NCT06829823","phase":"PHASE2","title":"Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":20},{"nctId":"NCT03022825","phase":"PHASE2, PHASE3","title":"QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2017-06-02","conditions":"Bladder Cancer","enrollment":190},{"nctId":"NCT07182838","phase":"EARLY_PHASE1","title":"Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-09-12","conditions":"HIV Infections","enrollment":20},{"nctId":"NCT07207824","phase":"PHASE3","title":"DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12-01","conditions":"Bladder (Urothelial, Transitional Cell) Cancer, NMIBC","enrollment":182},{"nctId":"NCT06781879","phase":"PHASE4","title":"Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Jakob Kristian Jakobsen","startDate":"2025-06-01","conditions":"Non-Muscle Invasive Bladder Cancer","enrollment":272},{"nctId":"NCT07189793","phase":"PHASE2","title":"Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2025-10","conditions":"Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Carcinoma in Situ of Bladder","enrollment":106},{"nctId":"NCT06704191","phase":"PHASE1, PHASE2","title":"In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-04-21","conditions":"Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8","enrollment":40},{"nctId":"NCT04149574","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2020-01-15","conditions":"Urinary Bladder Neoplasms","enrollment":13},{"nctId":"NCT06388720","phase":"PHASE2","title":"The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2024-11-19","conditions":"Bladder Cancer","enrollment":82},{"nctId":"NCT06351904","phase":"PHASE1","title":"A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy","status":"RECRUITING","sponsor":"Ractigen Therapeutics.","startDate":"2024-04-03","conditions":"Non-Muscle-Invasive Bladder Cancer (NMIBC)","enrollment":72},{"nctId":"NCT05126472","phase":"PHASE1","title":"Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-11-08","conditions":"Non-muscle Invasive Bladder Cancer","enrollment":55},{"nctId":"NCT07152639","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above","status":"RECRUITING","sponsor":"Chengdu CoenBiotech Co., Ltd","startDate":"2025-08-09","conditions":"Tuberculosis","enrollment":1784},{"nctId":"NCT05519241","phase":"PHASE1","title":"A Phase I Intravesical PPM Therapy for NMIBC","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2022-10-10","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":29},{"nctId":"NCT05704244","phase":"PHASE3","title":"Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2022-12-21","conditions":"Bladder Cancer","enrollment":25},{"nctId":"NCT05825950","phase":"","title":"Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-01-25","conditions":"Non-muscle-invasive Bladder Cancer","enrollment":600},{"nctId":"NCT05539989","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa","status":"WITHDRAWN","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2025-12-31","conditions":"Tuberculosis, HIV Infections","enrollment":0},{"nctId":"NCT07048496","phase":"NA","title":"Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-07-05","conditions":"Bladder Cancer","enrollment":50},{"nctId":"NCT07122414","phase":"PHASE1, PHASE2","title":"A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","startDate":"2024-08-16","conditions":"Non-muscle Invasive Bladder Cancer (NMIBC)","enrollment":80},{"nctId":"NCT05507671","phase":"PHASE3","title":"The Role of BCG Vaccine in the Clinical Evolution of COVID-19 and in the Efficacy of Anti-SARS-CoV-2 Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2021-05-27","conditions":"COVID-19","enrollment":556},{"nctId":"NCT07094711","phase":"PHASE2","title":"Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST)","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2025-09-30","conditions":"Mycobacterium Avium-intracellulare Infection, Mycobacterium Infections, Nontuberculous","enrollment":48}],"_emaApprovals":[{"date":"","name":"BCG","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[{"role":"Manufacturer","site":"Merck Sharp & Dohme LLC","location":"","operator":"Merck Sharp & Dohme LLC"}],"molecularData":{"oral":false,"chemblId":"CHEMBL2108905","moleculeType":"Vaccine component","molecularWeight":""},"administration":{"route":"Intravesical"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL2108905","pubchemSID":"539348"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"?-present","_source":"FDA label","companyName":"Merck Sharp & Dohme LLC","relationship":"Originator"}],"publicationCount":28546,"therapeuticAreas":["Oncology"],"atcClassification":{"atcCode":"L03AX03","atcName":"BCG vaccine"},"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Vaccine-derived therapy","firstApprovalDate":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"192700.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"Un","currency":"USD","price_amount":"57335.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"57335.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"57335.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"57335.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"57335.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:43:47.071345+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}